ClinicalTrials.gg
TerminatedNCT04832139Updated Jul 11, 2022

A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device

A Phase 1 interventional study of Marstacimab PFP and Marstacimab PFS in Healthy Volunteers, sponsored by Pfizer. Terminated at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-11.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Why this study was terminated
The study was terminated due to a change in the benefit/risk assessment for the further administration of marstacimab in a healthy volunteer population.

From the registry’s dates

  • Primary completion was Nov 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.

Enrollment
20th of 32
22 · median 34
Started
2021
with 2 others
Phase 1
5 of 47
1 open now
Registered
38th of 47
by date

Among the 47 studies in Hemophilia A by Pfizer, this one is the 20th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 in phase 1, and was the 38th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Hemophilia A by Pfizer, or all of them as a file.
02

Study summary

The goal in this study is to show that there are not significant differences in biologic activity of the study drug when administered using either the prefilled pen and prefilled syringe.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Bioequivalence
  • Phase 1
  • Prefilled Pen
  • Prefilled syringe
  • pharmacokinetic
  • subcutaneous
  • hemophilia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants who are overtly healthy as determined by medical evaluation
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • of 17.5 to 30.5 kg/m2; and a total body weight ≥ 50 kg (110 lb).
  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease
  • Any condition possibly affecting drug absorption (eg, conditions affecting SC administration)
  • Previous or current treatment for and/or history of coronary artery diseases, venous or arterial thrombosis, or ischemic disease.
  • History of infection, , or ; positive testing for HIV, HBsAg, HBcAb or HCVAb
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior, laboratory abnormality or COVID-19 related condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention
  • Previous administration with an drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  • A positive urine drug test at screening and/or admission
  • Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic)
  • Baseline 12 lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
  • Participants with ANY of the following abnormalities in clinical laboratory tests at screening:

    • or ALT level ≥1.5 × ;
    • Total level ≥1.5 × ULN.
  • An estimated (eGFR) of \<60 mL/min/1.73m2 based on the CKD-EPI equation.
  • Resistance to activated protein C (or Factor V Leiden mutation), prothrombin 20210 mutation, antithrombin III deficiency, protein C deficiency, or protein S deficiency.
  • Presence of Lupus anticoagulant anti-cardiolipin antibodies (IgG, IgM or IgA)
  • High sensitivity C-reactive protein (hsCRP) above the upper limits of normal
  • Abnormal hematology values as defined by the following laboratory tests at Screening and/or admission:

    • count \<100,000/uL
    • level \<10 g/dL
  • A positive COVID-19 test.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening
  • Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  • Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of the protocol
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Marstacimab Prefilled Pen (PFP), then marstacimab Preflled Syringe (PFS)

    Participants will first receive single dose PFP, then PFS, then repeating single dose PFP, then single dose PFS with a minimum of 21 days between single doses.

    Drug: Marstacimab PFP · Drug: Marstacimab PFS

  • Experimental
    Marstacimab PFS, then marstacimab PFP

    Participants will first receive single dose PFS, then PFP, then repeating single dose PFS, then single dose PFP with a minimum of 21 days between single doses.

    Drug: Marstacimab PFP · Drug: Marstacimab PFS

Interventions

  • 300 milligrams (mg) subcutaneous injection marstacimab PFP

    Also known as: PF-06741086

  • 300 mg subcutaneous injection of marstacimab PFS

    Also known as: PF-06741086

06

What researchers measure

Primary outcomes

  1. Area Under the plasma concentraiton time Curve from time zero extrapolated to infinite time (AUCinf)

    Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose

  2. Maximum observed plasma concentration (Cmax)

    Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose

Secondary outcomes

  1. Area under the concentration time curve from time 0 to time of last quatifiable concenteration

    Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose

  2. Time for Cmax

    Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose

  3. Apparent clearance after subcutaneous dose

    Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose

  4. Apparent volume of distribution after subcutaneous dose

    Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose

  5. Terminal half-life after subcutaneous dose

    Time frame: Day 1 Hour 0, 1, 2, 4, 8, 12, 24, 48, 72; Day 7; Day 14; Day 21 after each dose

  6. Incidence of clinically significant laboratory value abnormalities

    Time frame: Baseline through the end of study, approximately 161 days

  7. Incidence of anti-drug antibody against marstacimab

    Time frame: From Day 1, Period 1 through Day 21, Period 4 over a total of 84 days

  8. Incidence of Adverse Events

    Time frame: Baseline through the end of study, approximately 161 days

  9. Incidence of neutralizing antibody against marstacimab

    Time frame: From Day 1, Period 1 through Day 21, Period 4 over a total of 84 days

  10. Incidence of Serious Adverse Events

    Time frame: Baseline through the end of study, approximately 161 days

07

Study locations

1 site
  • Brussels Clinical Research Unit
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Nov 2021, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2021
First posted
Apr 5, 2021
StartActual
Mar 30, 2021
Primary completionActual
Nov 22, 2021
CompletionActual
Nov 22, 2021
Last update
Jul 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04832139
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 5, 2021
Start date
Mar 30, 2021
Primary completion
Nov 22, 2021
Completion
Nov 22, 2021
Last update
Jul 11, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Marstacimab

Start the discussion